Walleye Capital
BVS icon

Walleye Capital’s Bioventus BVS Stock Holding History

Walleye Capital’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,283
Closed -$77K – 3235
2022
Q2 		$77K Buy
+11,283
New +$115K ﹤0.01% 1783
2021
Q4 		– Sell
-10,769
Closed -$152K – 2115
2021
Q3 		$152K Buy
+10,769
New +$166K ﹤0.01% 1240

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Walleye Capital's BVS Position: Q3 2022 in Review

Walleye Capital sold out of Bioventus (BVS) in Q3 2022, closing a stake of 11,283 shares — an estimated $77K sold.

Walleye Capital first reported a position in BVS in Q3 2021 and held it in 2 quarters. The position peaked at $152K in Q3 2021. 94 funds tracked by Wall St. Rank hold BVS as of Q3 2022.

  • Walleye Capital reported no remaining Bioventus position as of Q3 2022 after selling out during the quarter.
  • Walleye Capital sold 11,283 Bioventus shares in Q3 2022, an estimated $77K.
  • Walleye Capital first reported a position in Bioventus in Q3 2021 and held it in 2 quarters.
  • Walleye Capital's Bioventus position peaked at $152K in Q3 2021.
  • 94 funds tracked by Wall St. Rank held Bioventus as of Q3 2022.

Based on Walleye Capital's 13F filing for Q3 2022, filed 14 Nov 2022.